CClinicalTrials.gg
Not yet recruitingNCT07752017Updated Aug 7, 2026

Validity and Reliability of the 2-Minute Step Test in Patients With Lipedema

An observational study in Lipedema, sponsored by Istanbul Physical Medicine Rehabilitation Training and Research Hospital. Not yet recruiting. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Istanbul Physical Medicine Rehabilitation Training and Research Hospital · Observational

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
55
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

Lipedema is a chronic, progressive adipose tissue disorder that predominantly affects women and is characterized by symmetric, disproportionate subcutaneous fat accumulation in the lower extremities, pain, tenderness, and easy bruising. It is associated with reduced mobility and impaired functional capacity. Although the 2-Minute Step Test (2MST) is a practical, low-cost measure of functional capacity that requires no equipment or large space, its validity and reliability have not been investigated in patients with lipedema. The aim of this study is to evaluate the construct validity and test-retest reliability of the 2MST in women with lipedema.

Read the detailed description

This prospective, cross-sectional study will enroll 55 women diagnosed with lipedema (stage 2 and above) according to the Wold and Halk-Damstra criteria. Participants will undergo the 2-Minute Step Test (2MST), the 6-Minute Walk Test (6MWT), the Timed Up and Go Test (TUGT), the Visual Analog Scale (VAS) for pain, and the Lower Extremity Functional Scale (LEFS). Vital signs (blood pressure, oxygen saturation, heart rate) will be checked before testing. Tests will be administered in a fixed order (2MST, then 6MWT, then TUGT) with at least 30 minutes of rest between them, by the same examiner, at similar times of day. To assess test-retest reliability, the 2MST will be repeated after a 7-day interval by the same examiner. Reliability will be evaluated using the intraclass correlation coefficient (ICC) with 95% confidence intervals, standard error of measurement (SEM), and minimum detectable change (MDC95). Construct validity will be evaluated using Spearman correlation coefficients between the 2MST and the 6MWT, TUGT, LEFS, and VAS.

02

Conditions studied

  • Lipedema

Browse trials for

03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

Patients with lipedema

Inclusion criteria

  • Clinically diagnosed with lipedema according to the Wold and Halk-Damstra criteria, stage 2 and above
  • Aged 18-65 years, female
  • No walking-limiting pathology
  • Willing to participate

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled hypertension
  • Decompensated cardiac failure
  • Systemic, degenerative, neurological, rheumatological, or orthopedic disease affecting lower-extremity function
  • Lower-extremity surgery within the past 6 months
  • Peripheral artery disease causing vascular claudication
  • Severe psychiatric disorder (active psychosis, severe major depression) or cognitive impairment preventing compliance with test instructions
  • Neuromuscular disease
  • Pregnancy
  • Advanced-stage lipo-lymphedema severely restricting ambulation
04

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
55 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes
05

What researchers measure

Primary outcomes

  1. 2-Minute Step Test (2MST)

    Functional exercise capacity assessed by the number of times the participant raises the knee to the required height during 2 minutes. Higher scores indicate better functional exercise capacity.

    Time frame: Baseline

Secondary outcomes

  1. 6-Minute Walk Test (6MWT)

    Functional exercise capacity assessed by the total distance walked in 6 minutes (meters). Greater walking distance indicates better functional capacity and endurance.

    Time frame: Baseline

  2. Timed Up and Go Test (TUGT)

    Functional mobility assessed by the time required to stand up from a chair, walk 3 meters, turn around, walk back, and sit down (seconds). Longer completion times indicate poorer functional mobility and balance.

    Time frame: Baseline

  3. Lower Extremity Functional Scale (LEFS)

    Self-reported lower extremity function assessed using a 20-item questionnaire with a total score ranging from 0 to 80. Higher scores indicate better lower extremity function and less disability.

    Time frame: Baseline

  4. Visual Analog Scale (VAS)

    Pain intensity assessed using a 100-mm visual analog scale ranging from 0 (no pain) to 100 (worst imaginable pain). Higher scores indicate greater pain intensity.

    Time frame: Baseline

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT07752017
Lead sponsor
Istanbul Physical Medicine Rehabilitation Training and Research Hospital
Responsible party
Sponsor
First posted
Aug 7, 2026
Start date
Aug 10, 2026 (estimated)
Primary completion
Apr 10, 2027 (estimated)
Completion
Apr 10, 2027 (estimated)
Last update
Aug 7, 2026

Study contacts

Merve Aydın, MD
Contact
merveay9702@gmail.com
2124445434
Nurdan Paker, Prof
principal investigator · Istanbul Physical Medicine Rehabilitation Training and Research Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion